Financial Performance Summary

FDC Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2026 (Q1 FY27).

Key Financial Metrics (Rs. in crores):

| Particulars | Q1 FY27 | Q1 FY26 | Y-o-Y Growth % |

| Revenue from Operations | 668 | 648 | 3.0% |

| EBITDA | 143 | 140 | 1.9% |

| EBITDA Margin | 21.4% | 21.6% | -20 bps |

| PBT | 175 | 160 | 9.4% |

| PAT | 132 | 121 | 9.2% |

| EPS (Rs.) | 8.14 | 7.45 | 9.2% |

Revenue Analysis

Revenue from operations increased by 3.0% year-over-year to Rs. 668 crores in Q1 FY27 from Rs. 648 crores in Q1 FY26. The growth was primarily driven by strong performance in International Formulations, particularly the US business, while Domestic Formulations and APIs remained relatively muted.

Segment-wise Performance

Business Segment Sales (Rs. in crores):

| Segment | Q1 FY27 | Y-o-Y Growth % | Contribution to Sales |

| Domestic Formulations | 569 | -1.9% | 85% |

| International Formulations (US) | 34 | 118.4% | 5% |

| International Formulations (Non-US) | 39 | 47.7% | 6% |

| APIs | 24 | -2.9% | 4% |

| Total International Formulations | 73 | 74.2% | 11% |

Domestic Formulations:

  • Revenue stood at Rs. 569 crores, reflecting a Y-o-Y decline of 1.9%
  • Performance was impacted by subdued performance in select key brands including Zifi, Enerzal and Simyl MCT
  • According to secondary sales data from IQVIA for QTR and MAT ended June 30, 2026, the Company recorded growth of 9.0% and 1.9% respectively

International Formulations:

  • Total sales stood at Rs. 73 crores, registering Y-o-Y growth of 74.2%
  • US business reported revenue of Rs. 34 crores, representing Y-o-Y growth of 118.4%
  • Non-US Export Formulations revenue stood at Rs. 39 crores, representing Y-o-Y growth of 47.7%
  • During the quarter, the Company received U.S. FDA approval for Cefixime for Oral Suspension USP 100mg/5mL and 200mg/5mL

APIs Business:

  • Recorded sales of Rs. 24 crores, reflecting a Y-o-Y decline of 2.9%

Profitability Analysis

EBITDA for Q1 FY27 stood at Rs. 143 crores, compared with Rs. 140 crores in Q1 FY26, reflecting Y-o-Y growth of 1.9%. EBITDA margin was 21.4% during the quarter, compared with 21.6% in the corresponding quarter of the previous year, representing a marginal contraction of 20 basis points.

Profit before tax increased by 9.4% Y-o-Y to Rs. 175 crores, while profit after tax increased by 9.2% Yo-Y to Rs. 132 crores. Earnings per share stood at Rs. 8.14, compared with Rs. 7.45 in Q1 FY26.

Company Background

FDC was established in 1936 as a partnership firm and incorporated as a Company in 1940. The company has accreditations from US-FDA, UK-MHRA, MCC-RSA, and the UAE. FDC is a forerunner in manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmics. The company has multi-location manufacturing facilities for APIs and Finished Dosage Formulations located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports to over 50 countries.

Forward-Looking Statements Disclaimer

The press release contains forward-looking statements that involve risks and uncertainties including the company's ability to implement strategy, growth and expansion plans, regulatory approvals, technological changes, earnings fluctuations, foreign exchange rates, international operations management, and market risks.